Ajooni Biotech Approves Capital Hike and Preferential Issue

Nature of Filing / Announcement: Outcome of Board Meeting under Regulation 30 of SEBI (LODR) Regulations, 2015

Not Specified

Capital Structure Changes:

Authorized Share Capital increased from ₹50,00,00,000 (50 crore) divided into 25,00,00,000 (25 crore) equity shares of ₹2 each to ₹70,00,00,000 (70 crore) divided into 35,00,00,000 (35 crore) equity shares of ₹2 each
Amendment to Clause V of Memorandum of Association to reflect new authorized capital

Preferential Issue:

Issue, offer and allot up to 90,00,000 (90 lakh) equity shares on preferential basis to promoter entity Healthy Biosciences Limited
Issue price: ₹4.30 per equity share, determined in accordance with SEBI ICDR Regulations
Total issue amount: ₹3,87,00,000 (3.87 crore)
Post-issue promoter holding will increase from 26.89% (4,63,24,766 shares) to 30.53% (5,53,24,766 shares)
Public holding will decrease from 73.11% to 69.47%
Total shares outstanding will increase from 17,22,43,598 to 18,12,43,598

Management Remuneration:

Proposal for revision/partial modification of terms and conditions of remuneration of Mr. Jasjot Singh, Managing Director, deferred for consideration at subsequent Board Meeting
Existing terms and conditions of his remuneration shall continue until further review

All proposals subject to shareholder approval at AGM on July 29, 2026
Necessary disclosures made as per SEBI Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 November 11, 2024 and SEBI Master Circular dated January 30, 2026